All the news Showing 10 of 26 articles from: CirrhosisGet an RSS feed of these articles Show All news infohep newsEditors' picks from other sources Curing hepatitis C reduces liver-related complications and death Liz Highleyman / 23 January 2017 People with hepatitis C who achieve sustained virological response to treatment had lower liver-related morbidity and mortality rates compared to people who were not successfully treated, according to research presented at the 2016 ... Improvements in HIV treatment and care have had no impact on rates of endstage liver disease among HIV-positive people with viral hepatitis Michael Carter / 01 September 2016 Incidence of endstage liver disease (ESLD) among HIV-positive people with viral hepatitis changed little between 1996 and 2010, despite major improvements in HIV treatment and care, investigators from Canada and the United States ... Statins reduce risk of progression to cirrhosis in people with HIV/HCV co-infection Michael Carter / 30 August 2016 Treatment with statins decreases the risk of progression to liver cirrhosis in people with HIV/hepatitis C virus (HCV) co-infection, investigators from the United States report in AIDS. The protective effect of statins was ... Antiviral therapies give Hepatitis C cirrhosis patients similar life expectancy as general population Manual Items / 05 May 2016 Liver cancer risk will remain elevated for people with cirrhosis cured of hepatitis C Keith Alcorn / 16 November 2015 The burden of liver cancer and cirrhosis caused by hepatitis C is likely to continue to grow in the United States despite curative treatment for hepatitis C, and people who have cirrhosis ... Dr. E Lebovics: Post-EASL 2015 HCV Interview American Journal of Medicine Hepatitis C Resource Center / 02 June 2015 Statin use associated with lower risk of liver decompensation and death in hepatitis C patients with cirrhosis Liz Highleyman / 19 May 2015 People with hepatitis and liver cirrhosis were significantly less likely to progress to decompensated disease and less likely to die if they used statins to control blood cholesterol, according to an analysis of ... Sofosbuvir, daclatasvir and ribavirin cures hepatitis C for most people with advanced cirrhosis or liver transplants Liz Highleyman / 29 April 2015 An interferon-free regimen of sofosbuvir, daclatasvir and ribavirin for 12 weeks produced sustained response rates of 83% for people with hepatitis C virus (HCV) who had advanced liver cirrhosis and 94% for ... Alcohol misuse the strongest predictor of severe liver damage and death in French people with hepatitis C Keith Alcorn / 28 April 2015 People with hepatitis C have a much greater risk of liver-related hospitalisation or death if they have an alcohol use disorder or another serious co-morbidity such as HIV infection, chronic kidney disease ... Sofosbuvir/ledipasvir with ribavirin is highly effective for people with decompensated cirrhosis Liz Highleyman / 12 November 2014 An oral regimen of sofosbuvir/ledipasvir plus ribavirin taken for 12 weeks cured most hepatitis C patients with decompensated cirrhosis, the most advanced stage of liver disease, according to a presentation ... ← Prev123Next → Other pages in this section Latest news All the news Hepatitis A Hepatitis B Hepatitis C Hepatitis D Hepatitis E Coronavirus NAFLD Treatment for hepatocellular carcinoma Transmission, epidemiology and prevention Health services, policy and advocacy Social issues Conference news Email bulletin archive